MF
KROS icon

Magnetar Financial’s Keros Therapeutics KROS Stock Holding History

Magnetar Financial’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,085
Closed -$332K – 1331
2026
Q1 		$332K Buy
+30,085
New +$465K ﹤0.01% 739

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Magnetar Financial's KROS Position: Q2 2026 in Review

Magnetar Financial sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 30,085 shares — an estimated $332K sold.

Magnetar Financial first reported a position in KROS in Q1 2026 and held it in 1 quarter. The position peaked at $332K in Q1 2026. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Magnetar Financial reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Magnetar Financial sold 30,085 Keros Therapeutics shares in Q2 2026, an estimated $332K.
  • Magnetar Financial first reported a position in Keros Therapeutics in Q1 2026 and held it in 1 quarter.
  • Magnetar Financial's Keros Therapeutics position peaked at $332K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Magnetar Financial's 13F filing for Q2 2026, filed 14 Aug 2026.